We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+3.15%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$120M
Cap. Flow
+$109M
Cap. Flow %
6.95%
Top 10 Hldgs %
44.48%
Holding
133
New
28
Increased
33
Reduced
33
Closed
26

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.1M
2
CLDX icon
Celldex Therapeutics
CLDX
+$25.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.7M
4
HQY icon
HealthEquity
HQY
+$12.8M
5
ARKK icon
ARK Innovation ETF
ARKK
+$9.18M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$60.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$27.8M
3
CTLT
CATALENT, INC.
CTLT
+$24.5M
4
LH icon
Labcorp
LH
+$23.9M
5
MASI
Masimo
MASI
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 72.04%
2 Industrials 1.19%
3 Technology 0.06%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
26
CALL
Community Health Systems
CYH
$385M
$17M 1.09%
1,277,200
+200,000
+19% +$2.51M
ICLR icon
27
Icon
ICLR
$12.8B
$16.1M 1.03%
51,867
-20,044
-28% -$5.61M
ELV icon
28
Elevance Health
ELV
$81.9B
$15.9M 1.02%
34,294
+2,666
+8% +$1.12M
ARKG icon
29
CALL
ARK Genomic Revolution ETF
ARKG
$1.51B
$14.9M 0.95%
+243,800
New +$16.9M
FATE icon
30
Fate Therapeutics
FATE
$281M
$14.9M 0.95%
254,790
-6,105
-2% -$346K
HQY icon
31
HealthEquity
HQY
$7.91B
$14.7M 0.94%
333,352
+218,974
+191% +$12.8M
LH icon
32
Labcorp
LH
$24.3B
$14.3M 0.91%
52,988
-96,366
-65% -$23.9M
XBI icon
33
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$12.7M 0.81%
+113,800
New +$13.7M
HUM icon
34
Humana
HUM
$46.7B
$12.7M 0.81%
27,382
+3,299
+14% +$1.46M
HCA icon
35
HCA Healthcare
HCA
$84.8B
$12.6M 0.81%
49,094
+10,728
+28% +$2.63M
ITCI
36
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.1M 0.78%
231,787
+1,043
+0.5% +$43.8K
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$36.3B
$11.9M 0.76%
70,240
+11,007
+19% +$2.05M
IONS icon
38
Ionis Pharmaceuticals
IONS
$9.35B
$11.7M 0.75%
384,789
-65,712
-15% -$2.07M
ARKK icon
39
ARK Innovation ETF
ARKK
$5.89B
$11.3M 0.72%
119,118
+84,118
+240% +$9.18M
NSTG
40
DELISTED
NanoString Technologies, Inc.
NSTG
$11.2M 0.72%
265,695
+97,027
+58% +$4.24M
GH icon
41
Guardant Health
GH
$19.5B
$10M 0.64%
100,334
-27
-0% -$2.79K
MGLN
42
DELISTED
Magellan Health Services, Inc.
MGLN
$9.95M 0.64%
104,700
– –
EXEL icon
43
Exelixis
EXEL
$13.9B
$9.79M 0.63%
535,700
+19,393
+4% +$371K
NTRA icon
44
Natera
NTRA
$37.5B
$9.53M 0.61%
102,071
-10,118
-9% -$1.05M
TARO
45
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$9.08M 0.58%
181,151
+1,785
+1% +$100K
QGEN icon
46
Qiagen
QGEN
$8.53B
$9.03M 0.58%
153,279
+18,319
+14% +$1.05M
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$8.95M 0.57%
550,966
-223,625
-29% -$3.28M
SYNH
48
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$8.79M 0.56%
+85,612
New +$8.22M
IRTC icon
49
iRhythm Holdings
IRTC
$3.59B
$8.61M 0.55%
73,169
-40,685
-36% -$3.73M
PODD icon
50
Insulet
PODD
$11.3B
$8.03M 0.51%
+30,172
New +$8.75M
1
2
3 4 5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Eversept Partners held 133 positions worth $1.57B, up 8.3% from $1.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Eversept Partners deployed $109M of net new capital in Q4 2021, opening 28 new positions and adding to 33 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 80% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Labcorp, an estimated $23.9M trimmed.

  • Eversept Partners's largest Q4 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $21.7M increase.
  • Eversept Partners's biggest Q4 2021 reduction was Labcorp, cutting an estimated $23.9M.
  • Eversept Partners fully exited Acceleron Pharma in Q4 2021, selling an estimated $60.1M.
  • Eversept Partners's ten largest holdings make up 44% of its $1.57B portfolio in Q4 2021.
  • Eversept Partners opened 28 new positions and closed 26 in Q4 2021.
  • Eversept Partners's portfolio value rose 8.3% quarter-over-quarter to $1.57B.

Based on Eversept Partners's 13F filing for Q4 2021, filed 14 Feb 2022.